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Department. Fundacio´n Jime´nez Dı´az. Madrid. Spain.
Although autoantibody detection has been proposed for diagnosis of colorectal cancer, little is known about
their initial production and development correlation with cancer progression. Azoxymethane/dextran
sodium sulfate (AOM/DSS)-treated mice developed colon adenocarcinoma in the distal colon similar to
human sporadic colon cancer. We assessed this model together with AOM and DSS-only models for their
applicability to early detection of cancer. All AOM/DSS-treated mice produced autoantibodies to
tumor-associated antigens analogous to those observed in human colon cancer patients. Autoantibody
response was related to tumor antigen overexpression. Cancer autoantibodies were detected 21 days after
starting treatment, when no malignant histopathological features were detectable, and they increased
according to tumor progression. When carcinogenesis was induced separately by AOM or DSS, only those
mice that developed malignant lesions produced significant levels of autoantibodies. These findings
demonstrate that autoantibody development is an early event in tumorigenesis and validates its use for
preclinical colon cancer diagnosis.
C
ancer patients develop an immune humoral response against tumor-associated antigens (TAAs).
Autoantibody responses have been mainly associated to cancers with an elevated inflammatory compon-
ent such as colon1–3, prostate4, ovarian5,6, lung7,8 or breast cancer9, among others. In addition to elevated
specificity and sensitivity, advantages of this strategy include easy and minimally invasive sample collection for
diagnosis. Moreover, the long stability of the antibodymolecules allows for retrospective studies in samples stored
for long periods10,11. We hypothesized that murine colon cancer models could mimic the human humoral
response to cancer and provide us with a clear insight into the production, kinetics and evolution of autoantibody
development, including a clear answer to their potential application to cancer diagnosis in preclinical and early
colon cancer stages.
We used azoxymethane (AOM) and dextran sodium sulfate (DSS), individually or in combination, to generate
different inducible mouse models of colon cancer in order to study the effect of carcinogenicity and/or inflam-
mation on the induction of autoantibodies. AOM is a chemical agent that initiates cancer by alkylation of DNA,
favoring the introduction of mutations12. Intraperitoneal administration of 3 to 6 AOM-only injections induces
the development of spontaneous tumors in distal colon within 7-10 months depending on the mouse strain13. On
the other hand, DSS supply in drinking water induces inflammatory cell infiltration of the mucosa propia,
ulceration and bloody diarrhea14. DSS disrupts the colon epithelial lining, provoking severe colitis and ulcerative
colitis-like neoplasia lesions mainly found in the distal colon15,16. Administration of 3 to 4 and up to 9 DSS cycles
in drinking water results in the development of colorectal dysplasia and adenocarcinoma in a subset of treated
mice14,17. Number, severity of lesions and percentage of affected mice depends on the mouse strains14,17,18.
The combined treatment with AOM/DSS is currently used as a common mouse model of colitis-associated
colon cancer (CAC). Tumors induced by AOM/DSS occur preferentially at the distal part of the colon, which is
the predominant localization of spontaneous colorectal cancer (CRC) in humans. Althoughmetastasis is very rare
in this model19, many steps in cancer development including formation of aberrant crypt foci, polyps, adenomas
and carcinomas are shared betweenCRC andCAC. It has been extensively used for the study of inflammation and
its association with colon cancer development20,21. This model has been very useful for the elucidation of the role
of TNF-a, IL6, NFkB and other molecules in the initiation and promotion of inflammation-associated tumor
growth (see22 for a review), but it has not been applied for autoimmunity and biomarker studies. Tumor
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development takes less than 10 weeks and the number and severity of
lesions depends on the susceptibility to AOM and DSS of the mouse
strain12. Ten weeks should be long enough for the production and
evaluation of specific antibodies to tumor antigens.
In addition, in this report we tested a surface variant of protein
microarrays for autoantibody detection in colon cancer. We iden-
tified three novel TAAs: EDIL3, GTF2B and HCK. Combining these
three antigens with previously identified TAAs2,3,23, NY-ESO-124, and
p531,9,25, we studied the humoral response in mouse models devel-
oping dysplasia or adenocarcinoma in distal colon. The mouse hum-
oral response gave a reactivity profile similar to that observed in
human CRC patients. Moreover, autoantibody titers preceded clin-
ical symptoms and correlated with the type and grade of lesions in all
three experimental groups tested, and their levels went parallel to
tumor development. The use of AOM- and DSS-only treated mice
confirmed the predictive value of the autoantibodies.
Results
A colitis-associated cancer mouse model develops autoantibodies
to tumor-associated antigens.We tested the CACmouse model for
the presence of diagnostic autoantibodies. FVB/N mouse strain was
selected due to its good susceptibility for tumor formation. After
AOM/DSS treatment (Fig. 1a), all mice developed well-differenti-
ated adenocarcinomas in the distal colon, similar to those observed
in CRC patients. AOM/DSS-treated mice autoantibody responses
were analyzed with p53, STK4/MST1, MAPKAPK3, SRC, and NY-
ESO-1 as colon cancer TAAs and two negative controls (GST and
Annexin IV) (Fig. 1b). In addition, we also tested EDIL3, GTF2B and
HCK, which were here identified after analysis of the immune
response of CRC patients and controls with high-density protein
microarrays (see Supporting Note 1 for further details, Supplemen-
tary Fig. S1, Supplementary Table S1 and Supplementary Table S2).
We used human antigens for the ELISA because of the high amino
acid identity with their murine orthologs, going from 76% (p53) to
99% (GTF2B) (Supplementary Table S3). All mouse developed auto-
antibodies against human TAAs. Best differential values were
obtained for p53, GTF2B and STK4/MST1 (mean ELISA values
0.34 versus 0.05, 0.42 versus 0.01, and 0.41 versus 0.01 for AOM/
DSS treated mice and non-treated control mice, respectively; with p
values ,0.001 (Supplementary Fig. S3). Regarding NY-ESO-1, we
observed a weak response due, probably, to the lower amino acid
identity (29%) with its potential mouse counterpart (Supplementary
Table S3). No specific reactivity was observed against control anti-
gens GST and Annexin IV. Therefore, mice also reproduced the lack
of response to Annexin IV observed in human CRC patients2.
Collectively, these results showed that AOM/DSS-treated mice
developed a humoral response that followed a specificity pattern
similar to human CRC patients.
Autoantibody production is associated to antigen overexpression.
Then, we studied the association between autoantibody induction
and changes in protein and gene expression. Distal colon mucosa
from AOM/DSS- and vehicle-treated control mice were analyzed for
alterations in the expression of TAAs at protein (Fig. 1c) and mRNA
level (Fig. 1d). At protein level, a clear overexpression was observed
for p53, MAPKAPK3, and EDIL3 in AOM/DSS-treated mice in
cancer tissues, whereas MST1/STK4 and GTF2B showed almost no
alterations in their expression, and SRC decreased in cancer tissue.
Regarding mRNA expression, we observed overexpression for p53,
MAPKAPK3 and EDIL3. Again, GTF2B and MST1/STK4 showed
almost no alterations in their expression levels. These findings
support that autoantibody induction mostly associated to an
increase in the expression of TAAs. However, since autoantibodies
to SRC, MST1/STK4 and GTF2B were detected without protein or
mRNA overexpression, we cannot exclude other reasons (mutations,
wrong conformation or altered post-translational modifications …).
Autoantibody production occurs early in tumor development and
before neoplastic lesions. To test the value of autoantibodies for
early cancer detection we analyzed the kinetics of antibody
synthesis in the AOM/DSS murine model (Fig. 2a). Samples at day
21 post-inoculation of AOM (after the first cycle of DSS), day 42
(after the second cycle) and day 63 (after the third cycle) were
analyzed to quantify the antibody response in AOM/DSS-treated
(n 5 9) and control mice (n 5 9). Autoantibodies were already
detected at day 21 and their levels increased in parallel to the
progression of the disease from day 21 to day 63 (Fig. 2a). At day
21, an early antibody response against p53 and GTF2B was observed,
showing a clear difference between AOM/DSS-treated (mean ELISA
value: 0.24 and 0.22, respectively) and non-treated mice (mean: 0.02
and 0.09, respectively), with p value: 0.018 and 0.029, respectively
(Fig. 2b and Supplementary Fig. S4). Responses to STK4/MST1 and
EDIL3 were lower, suggesting a slower antibody induction for these
two TAAs. Thus, antibodies to p53 and GTF2B distinguished cancer
from control mice as soon as 21 days after AOM injection and 1 cycle
of DSS (Fig. 2b and Supplementary Fig. S4).
Then, we correlated the appearance of dysplasia or neoplastic
lesions in the distal colon of AOM/DSS-treated mice with autoanti-
body detection. At day 21, when autoantibodies were initially
detected, there were no noticeable neoplastic lesions or dysplasia in
the colon (Fig. 2c). Microadenomas with focal dysplasia in 2 out of 4
animals were firstly detected at day 27, before the second DSS cycle.
After the second DSS cycle (day 35), the distal colon of 2 AOM/DSS-
treated mice presented clearly infiltrating tumors, arising in more
extensive adenomatous areas with high grade dysplasia, which pro-
gressed to adenocarcinoma at day 48. At day 63, the adenocarcinoma
invaded the muscular layer (Fig. 2c). The presence of adenocarcino-
mas was coincident with high antibody titers. Collectively, these
results indicated that the autoantibody production against TAAs
took place before histopathological manifestations and clinical signs
were visible and increased in parallel to the progression of the disease.
In summary, the humoral response preceded clinical symptoms con-
firming their capacity for very early CRC diagnosis.
Predictive value in other sporadic cancer models. Since tumor for-
mation occurred in all mice treated with AOM/DSS, we investigated
the capacity of autoantibodies for predicting sporadic cancer in
animals that do and do not develop cancer. We used two protocols
(Fig. 3a): i) 3 cycles of DSS-only administration, without AOM (DSS
mice group), and ii) 6 weekly intraperitoneal injections of AOM-only
(AOM group) to study the individual contribution of AOM
mutagenesis and DSS inflammation in the development and produc-
tion of autoantibodies. In these two cases not all the animals develop
dysplastic symptoms, which facilitates the establishment of correla-
tions between autoantibody production and cancer development.
Mice were histologically examined at days 63 and 250, corres-
ponding to the expected dates for tumor development in DSS and
AOM groups, respectively. At day 63, DSS-treated mice showed a
whitened, thicker and notably shorter distal intestine, indicating a
large bowel inflammation (Fig. 3b). However, histological analysis
showed that 3 out of 5 DSS-only mice (DSS 1, DSS 2 and DSS 3)
developed intramucous adenomas in the distal colon, with mild dys-
plastic lesions or moderate-severe dysplasia (Fig. 3c). On the other
hand, DSS 4 showed low grade dysplastic, nonmalignant lesions and
DSS 5 showed a normal mucosa. Regarding the AOM-treated group
(n5 7), two mice inspected at day 63 did not show macro- (Fig. 3b)
or microscopic lesions in the distal colon (Fig. 3c). However, at day
250, threemice (AOM2, AOM3 andAOM5) showedmacroscopical
encapsulated and deeply irrigated polypoid cauliflower-like adeno-
mas in the distal colon (Fig. 3d). These three AOM-treated mice
presented infiltrating, but non-invasive tumors, where muscularis
propria was perforated in AOM 5 mouse (Fig. 3d). All lesions
presented cribriform pattern indicating gland degeneration and
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Figure 1 | Presence of autoantibodies in mice with colitis-associated cancer. (a) Schematic overview of the AOM/DSS colorectal cancer model. Each
rectangle represents one week. After an initial AOM injection (10 mg/kg), DSS was given in drinking water for a 2.5% final concentration (gray areas)
followed by regular water. Histological staining for distal colonmorphology and blood collectionwas performed at indicated days (black arrows). (b) Sera
collected after the thirdDSS cycle (day 63) from 16AOM/DSS-treatedmice developing colorectal adenocarcinoma showed specific reactivity against p53,
HCK, GTF2B, EDIL3, MST1/STK4, SRC and MAPKAPK3 with Annexin IV and GST as negative controls. Sera were tested by indirect ELISA using
purified human recombinant proteins. NY-ESO-1 showed a weak response. Results are representative of two independent assays. C, vehicle-treated
control mice. AD, AOM/DSS-treated mice. (c)Western blot analysis showed alterations in expression of p53, MAPKAPK3, MST1/STK4, EDIL3, GTF2B
and SRC in distal colon from 5 AOM/DSS-treated and 5 control mice. Tubulin was used as loading control in the same gels. (d) Semi-quantitative PCR
analysis showing mRNA expression in the distal colon tissue of AOM/DSS- and control mice. b-actin was used as a control. (c, d) WB and semi-
quantitative PCR analyses were quantified by densitometry and normalized according to the expression of tubulin and b-actin, respectively. For the
cropped images, samples from treated and control animals were run in the same gels under same experimental conditions and processed in parallel.
Experiments were run in duplicate.
www.nature.com/scientificreports
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mitotically active cells (Fig. 3d). Visually, the remainingmice showed
small (AOM 1) or no macroscopical lesions (AOM 4). However, by
histological staining, AOM 1 and AOM 4 showed small adenomas
(Fig. 3d).
Regarding autoantibody production, all mice were tested at day 63
(Fig. 4a) and AOM-treated mice were also tested at day 250 (Fig. 4b).
In DSS group, autoantibody levels correlated with the presence of
adenomas and dysplasia in the distal colon (Fig. 3b, c). These DSS-
treated mouse developed autoantibodies, although at lower titers
than AOM/DSS-treated mice (Fig. 4a and Supplementary Fig. S5).
At day 63, AOM group did not develop autoantibodies, correlating
with the absence of neoplastic lesions in the animals. However, at day
250, a significant presence of autoantibodies was found in those
AOM-treated mice presenting colon adenocarcinomas, except
AOM 4 mouse presenting a flat adenoma by histological staining
and no visually noticeable lesions (Fig. 4b and Supplementary Fig.
S6). These results demonstrated the high correlation between colon
cancer lesions and autoantibody induction, independently from the
tumorigenesis, and confirmed the strong predictive value of the
autoantibody response for cancer detection.
Discussion
In this report, we demonstrate that mice treated with different indu-
cible models of colon carcinogenesis developed a humoral immune
response, which was similar to that observed in human colon cancer
patients. Moreover, the induction of autoantibodies in AOM/DSS-
treated mice occurred at very early stages and was parallel to the pro-
gression of the disease. Autoantibodies were detected before the onset
of cancer lesions and the reactivity pattern was analogous to the hum-
oral immune response found in human colorectal cancer patients.
Experiments with DSS-only and AOM-only mice, where not all ani-
mals developed tumors, confirmed the high correlation between
tumor formation and autoantibody induction. Only those mice show-
ing adenomas and malignant dysplastic lesions developed significant
levels of autoantibodies. In this regard, some mice that developed
bowel inflammation without neoplasia, particularly in the DSS-only
model, failed to develop antibodies. Besides, the level of autoantibodies
in these two variants was lower than in AOM/DSS-treated mice and
suggests that different treatments might result in variable responses,
probably due to subtle differences in the TAAs being present in the
swollen, dysplastic tissue, adenoma or colorectal cancer tumors.
Figure 2 | Antibody response to colorectal cancer TAAs is detected before adenoma formation and increases according to tumor progression.
(a) Kinetics of antibody response to p53, GTF2B,MST1/STK4 and EDIL3.Murine sera were tested by indirect ELISA at a 15100 dilution. Autoantibodies
showed an increase in autoantibody production parallel to tumor progression. (b) Results representative of two independent assays using murine sera
collected at day 21 from 9 AOM/DSS-treated mice and 9 control mice. Annexin IV and GST were used as negative controls. (c) Histological staining of
distal colon morphology of AOM/DSS-treated mice at different days to monitor tumor progression. Mice before the second DSS cycle (day 27) showed
low levels of dysplasia and early adenoma development (black arrow), with focus of microinfiltration and different degrees of inflammation. During the
second cycle of DSS (day 35 to 48), dysplasia became of higher grade in clear-cut adenomatous lesions (black arrow) that progress to well-differentiated
adenocarcinoma (black arrow) with invasion of the muscular layer after the third DSS cycle (day 63). Images are shown at 200x magnification.
www.nature.com/scientificreports
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Figure 3 | DSS-only and AOM-only models of sporadic colon carcinogenesis. (a) Top, AOM (10 mg/kg) was weekly injected during six weeks. Bottom,
fresh 2.5% DSS was given in drinking water during five-day cycles (gray areas) followed by regular drinking water for 16 days. Blood samples were
collected at the end of the protocols and also for AOM-treated mice at day 63. (b) Representative images of distal colon macroscopic appearance of DSS-
treated (day 63) and AOM-treated mice at day 63 and 250. Tumors are highlighted with black arrows. (c) Representative haematoxylin/eosin staining
sections of distal colon morphology of DSS- and AOM-treated mice and control mice. No significant changes were observed for AOM-treated mouse at
day 63. DSS-treatedmice showed presence of adenomas and different grade of dysplasia (DSS 1,DSS 2 andDSS 3) at day 63, whereasDSS 4 animal showed
low grade nonmalignant dysplastic lesions and DSS 5 showed no changes respect to normal mucosa. (d) At day 250, three AOM-treated mice showed
infiltrating but non-invasive tumors (AOM2, AOM3 and AOM5), whereas the remaining animals (AOM1 and AOM4) showed small flat non-polipoid
adenomas with dysplasia. (c, d) Black arrows highlight the observed lesions. Images are shown at 200x magnification.
Figure 4 | Presence of autoantibodies in AOM- or DSS-only treated FVB/Nmice correlate with the presence of cancer-like lesions. Sera collected from
DSS-, AOM- and vehicle-treated control mice were investigated for autoantibodies to p53, MST1/STK4, EDIL3, GTF2B and HCK by indirect ELISA and
GST as negative control. Results are representative of two independent assays. (a) ELISA values at day 63 indicated the presence of significant levels of
autoantibodies in animals of the DSS-treated mice group that showed adenomas with mild or moderate-severe dysplasia in the distal colon. DSS 4 and
DSS 5 animals, showing non-malignant lesions and normal mucosa, respectively, as well as control group and AOM-treated mice did not develop
autoantibodies at day 63. (b) ELISA values at day 250 indicated the presence of significant levels of autoantibodies in AOM-treatedmice in comparison to
control mice.
www.nature.com/scientificreports
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The utility of autoantibodies for early detection of cancer has been
questioned for a long time, as the access to preclinical collection of
sera is difficult. In general, sample collection from the same patient,
before and after tumor development and during all tumor stages, is
not generally available, making almost impossible to determine the
exact moment when the autoantibodies appear and their correlation
with tumor progression. Only a few reports described the use of
autoantibodies in early diagnosis of cancer10,26. Autoantibodies to
annexin I, 14-3-3 Theta and LAMR1 were detected in prediagnostic
lung cancer sera using sera collected 1 year before the diagnosis of
lung cancer26. Furthermore, antibodies to p53, c-myc and MUC1
were detected in women between 7 and 27 months before breast
cancer was diagnosed10. However, no direct link between antibody
generation and early dysplastic events was previously reported. Here,
by using the AOM/DSS murine model, we provide evidence of the
immediateness of the antibody response, detectable at day 21 after
neoplastic transformation. This very early response confirms the
exquisite sensitivity of the immune system and suggests that only a
few tumor cells, undetectable by other means, are required for local
antigen processing by the immune system.
Genetic homogeneity and the lack of environmental mutagens in
the AOM/DSS mouse model avoid the high variability observed in
the human antibody response and facilitate the production of repro-
ducible results from mouse to mouse. Our study also supports that
murine sera could be used for testing different TAAs coming from
different studies, enabling the standardization and validation of TAA
selection. An exception to this could be the cancer-testis TAAs. Due
to the absence or low homology of murine orthologs; in fact, we
noticed a low response to NY-ESO-1.
The role of autoantibodies in cancer is still unclear. It is unknown
if they play a cancer-promoting role, an anti-tumoral effect, or they
are an epiphenomenon associated to inflammation and tumor pro-
gression27. The capacity of the mouse model to mimic extremely well
the human humoral response to TAAs paves the way to dissect the
molecular mechanisms of the autoantibody response in cancer
patients. Interestingly, one characteristic of the AOM/DSS model
is the very low frequency of mutations in p5313,28–30. However, we
and others have observed significant increases in p53 expression29–31,
which might be explained by accumulation of mutant p53 due to
lower degradation (Fig. 1b). Previous observations showed that there
were not significant differences between mutant forms or wild-type
p53 for autoantibody recognition in human sera32. Additional factors
such as incorrect folding, incorrect conformation or post-trans-
lational modifications may account for this reactivity.
Inflammation is a common event in tumor development, espe-
cially in the gastrointestinal tract33. Little is known about the link
between inflammation, autoimmunity and autoantibody production
in cancer. Murine colon cancer models might help to understand the
molecular basis of this process and study the association between
inflammation, autoantibody production and cancer progression.
The AOM/DSS models are characterized by the activation of NF-
kB, STAT3 and expression of high levels of IL-634. Activation of IL-6
receptor results in different signaling events that lead to the induction
of autoimmunity mediated by Th17 cells35. Therefore, IL-6 might
promote these autoantibody responses in cancer. The characteriza-
tion of these events in cancer autoimmunity will require further
studies. According to our results, inflammation seems to be a driver
of autoantibody induction, although not sufficient in some cases.
As main conclusion of this study, we have demonstrated the very
early induction of autoantibodies in cancer, which confirms the dia-
gnostic value of this approach for pre-clinical detection of human
colon cancer. The presence of autoantibodies was associated to the
neoplastic changes, independently from their origin. Thus, autoanti-
body tests could be recommended to identify cancer-carrier indivi-
duals in a first screening of the population. These findings should be
further confirmed by colonoscopy and/or other imaging techniques.
Methods
Clinical Information of serum samples for protein microarrays and statistical
analysis. The Institutional Ethical Review Boards of the Centro de Investigaciones
Biolo´gicas (CIB) and the Spanish National Research Council (CSIC) approved this
study on biomarker discovery in colorectal cancer. See supplementary online data for
additional information.
Murine colon cancer models. For the AOM/DSS model, we followed a published
protocol36, with minor modifications. Briefly, FVB/N mice (4–6 weeks-old) were
weighed and given a single intraperitoneal injection of azoxymethane (AOM; 10 mg/
kg) or vehicle (PBS). Five days later, animals received either 2.5% DSS or normal
drinking water, respectively. Chronic colitis and colon cancer were induced after
three cycles of DSS treatment, which consisted of 5 days of 2.5% freshDSS followed by
16 days of normal drinking water. Blood was collected at the starting day of the
experiment and 1 week after every DSS cycle.
To test separately the effects of AOM and DSS in the production of autoantibodies
and the development of cancer-like lesions in the FVB/N strain we followed two
protocols: i) one intraperitoneal injection of AOM (10 mg/kg) once a week for 6
weeks and then maintained up to 250 days, and ii) 3 cycles of 2.5% DSS as above
without the AOM injection and maintained during the same time than AOM/DSS
murinemodel (63 days). Bloodwas collected at the starting day and at the endpoint of
the experiments, or alternatively, at indicated times. We euthanized several treated
and control animals at the indicated times to monitor tumor progression by histo-
logical staining. In those specific days, their blood and tissues were harvested. At the
end of the protocols, we collected samples for all mice. Distal colons from all mice
were longitudinally cut, rinsed twice with ice-cold PBS, cut in small pieces and either
frozen at 280uC for RNA and protein extraction or fixed in 10% buffered formalin
overnight to perform histological staining after paraffin embedding. Serum samples
were processed according to standard procedures2.
Protein expression and RNA extraction. cDNA encoding for full-length human
genes EDIL3, GTF2B and HCK in pDONR221 were obtained from the PlasmId
repository (Harvard Institute of Proteomics) and, then, subcloned into pET28a
(Novagen) for protein expression. TAAs were expressed in bacteria and purified
according to previous studies2,3. p53 and NY-ESO-1 expressed as GST fusions in
baculovirus were purchased from Interchim and Thermo Scientific, respectively.
RNA was extracted from colon distal tissue from AOM/DSS- and vehicle-treated
control mice with the AllPrep DNA/RNA Mini Kit (Qiagen).
ELISA experiments. ELISA was carried out as previously described2,3. Briefly,
microtiter plates (Maxisorp, Nunc) were coated overnight with 0.3 mg of the purified
recombinant proteins, using GST and human Annexin IV as negative controls in
50 ml of PBS. After washing three times with PBS, plates were blocked with 3%
skimmed milk in PBS (MPBS) for 2 h at room temperature. Then, mouse serum
samples (dilution, 15100 in 3% MPBS) were incubated for 2 h at room temperature.
After washing, peroxidase-labeled anti-mouse IgG (Jackson laboratories) (dilution,
15500 in 3% MPBS) was added for 2 h at room temperature. Then, the signal was
developed with 3, 39, 5, 59-tetramethylbenzidine substrate for 10 min (Sigma). The
reaction was stopped with 1 M HCl, and absorption measured at 450 nm.
All p values were derived from a one-tailed statistical test assuming unequal var-
iances to assess whether the means of groups were statistically different from each
other. p values,0.05 were considered statistically significant. Each individual marker
and the combination of biomarkers were evaluated from murine ELISA data sets by
ROC curve analysis. The corresponding AUC, sensitivity and specificity were cal-
culated using JMPH 10 (SAS).
Western blot analysis. Protein extracts from colorectal cancer cells were prepared
and quantified with the 2D-Quant kit (GE Healthcare) according to previously
published protocols2,37. Then, 25 mg of each protein extract were run in parallel using
10% SDS-PAGE. For immunoblotting, proteins were transferred to nitrocellulose
membranes (Hybond-C extra) using wet transfer equipment (Bio-Rad). After
blocking, membranes were incubated with specific mono- or polyclonal antibodies
against the selected proteins. Membranes were incubated at optimized dilutions with
primary antibodies followed by incubation with either HRP-anti-mouse IgG (Pierce)
at 155000 dilution or HRP-anti-rabbit IgG (Sigma) at 155000 dilution. Specific
reactive proteins were visualized with SuperSignal West Pico Maximum Sensitivity
Substrate (Pierce).
The abundance of the proteins in western blot assays was quantified by densito-
metry using Quantity One 1D Analysis Software v4.6 (Bio-Rad Laboratories).
Semiquantitative RT-PCR analysis. PCRs were performed as previously
described38,39. Briefly, 1 mg of RNA from distal colon tissue from AOM/DSS-treated
and vehicle-treated control mice were reverse transcribed by using Superscript III
(Invitrogen). Oligonucleotides for murine TAAs were designed by using PrimerBlast
(Supplementary Table S4). For RT-PCR analysis, 0.8 ml of cDNA was subjected to
PCR using KOD DNA polymerase (Novagen) in a total volume of 20 ml to amplify
murine p53, GTF2B, EDIL3, STK4/MST1 and MAPKAPK3 with specific primers
(Supplementary Table S4). The PCR consisted of 30 cycles of amplification at 68uC of
annealing temperature. Finally, 5 ml of the previous reaction were loaded onto a 1.5%
agarose gel. Murine b-actin was used as control. Semi-quantitative PCR analyses were
quantified by densitometry using Quantity One 1D Analysis Software v4.6 (Bio-Rad
Laboratories).
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Immunohistochemistry. Distal colon from AOM-, DSS-, AOM/DSS- and vehicle-
treated control mice were fixed in buffered formaldehyde and paraffin-embedded.
Immunohistochemistry was performed on 6 mm sections of the blocks following an
automated method (Dako Autostainer). We counterstained the slides with
hematoxylin. In all cases, an external negative control was included.
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